Company Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on the development of novel biologic medicines for the treatment of cancer and immune-mediated diseases. The company operates within the biotechnology and immuno-oncology industries, with a primary emphasis on leveraging engineered fusion proteins to modulate immune system signaling pathways. Its core innovation is the ARC (Agonist Redirected Checkpoint) platform, which is designed to create multifunctional biologics that combine immune checkpoint blockade with immune activation.

Shattuck Labs was founded in 2016 and became a publicly traded company in 2020. The company’s strategy evolved from a broad immunotherapy pipeline toward a more concentrated focus on select clinical-stage oncology programs following strategic restructuring and workforce reductions disclosed in public filings. Its positioning centers on differentiated protein engineering intended to address limitations of conventional monoclonal antibodies by enabling dual or multi-target engagement within a single therapeutic.

Business Operations

The company’s operations are centered on research and development, with no commercialized products to date. Shattuck Labs generates no product revenue and relies primarily on capital raised through equity offerings and collaborations to fund operations. Its lead clinical programs are derived from the ARC platform, which combines tumor-targeting and immune co-stimulatory or checkpoint-modulating functions into a single molecule.

Operationally, Shattuck Labs conducts early- and mid-stage clinical trials, primarily in oncology indications such as hematologic malignancies and solid tumors. Research and development activities are conducted internally and through third-party contract research organizations. The company does not currently report distinct operating segments beyond its unified R&D-focused business model. Data on long-term commercial manufacturing or distribution assets remains inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Shattuck Labs has prioritized advancing its most clinically mature assets while reducing expenditure on earlier-stage or non-core programs. Its lead asset, SL-172154, is a multifunctional fusion protein designed to target both innate and adaptive immune pathways and has been evaluated in multiple clinical studies, including in combination with other oncology agents. The company has publicly stated its intent to seek strategic alternatives, partnerships, or additional capital to support continued development.

Shattuck Labs has historically entered into research collaborations and licensing agreements to validate its platform technology, though no large-scale acquisitions have been completed as of the most recent disclosures. The company’s investment focus remains on immuno-oncology and immune signaling biology, with emerging applications explored selectively as resources permit. Information regarding future acquisitions or late-stage investments is limited and cannot be conclusively verified from current public disclosures.

Geographic Footprint

Shattuck Labs is headquartered in the United States, with its principal executive offices located in Durham, North Carolina. Its operational footprint is primarily domestic, with laboratory, administrative, and clinical management functions based in the U.S. Clinical trials sponsored by the company have included investigational sites in North America and Europe, reflecting an international clinical development reach.

While the company does not maintain significant physical infrastructure outside the U.S., it exerts international influence through global clinical trial participation and relationships with overseas research institutions and contract service providers. There is no verified evidence of standalone international subsidiaries with independent commercial operations.

Leadership & Governance

Shattuck Labs is led by an executive team with experience in biotechnology development, corporate strategy, and capital markets. The company is governed by a board of directors that includes industry executives and investors with backgrounds in life sciences and healthcare. Leadership has emphasized capital discipline, scientific differentiation, and strategic optionality as core elements of its operating philosophy.

Key executives include:

• Taylor Schreiber, MD, PhD – Chief Executive Officer
• Mark A. Velleca, MD, PhD – President (former; role status subject to change based on recent restructuring disclosures)
• Andrew J. Goldberg – Chief Financial Officer
• Arthur Tzianabos, PhD – Chief Scientific Officer

Certain executive roles and responsibilities have changed over time due to restructuring activities, and some leadership information may vary across reporting periods. Data inconclusive based on available public sources where recent updates have not been consistently reported.